Description
Product Overview / 商品概要
Ceredist Tablets 5mg (セレジスト錠5mg)
Generic: Taltirelin Hydrate / タルチレリン水和物
Therapeutic Category: Oral Spinocerebellar Degeneration Treatment Agent / 経口脊髄小脳変性症治療剤
Manufactured by: Tanabe Pharma Corporation / 田辺ファーマ株式会社
Composition & Specification / 組成・規格
Active Ingredient: Taltirelin Hydrate (JP) 5mg per tablet / タルチレリン水和物 日局 5mg(1錠中)
Additives: Magnesium stearate, Corn starch, Povidone, D-Mannitol / ステアリン酸マグネシウム、トウモロコシデンプン、ポビドン、D-マンニトール
Appearance: White plain tablet (scored), Identification code: TA137, Diameter: 7.0mm, Thickness: 3.0mm, Weight: 0.12g
外観: 白色・素錠(割線入)、識別コード: TA137、直径7.0mm、厚さ3.0mm、重量0.12g
Indications / 効能効果
EN: Improvement of ataxia in spinocerebellar degeneration
JA: 脊髄小脳変性症における運動失調の改善
Dosage and Administration / 用法用量
EN: Usually, adults take 5mg of Taltirelin Hydrate per dose, twice daily (morning and evening) orally after meals. Dosage may be adjusted according to age and symptoms.
JA: 通常、成人にはタルチレリン水和物として1回5mg、1日2回(朝、夕)食後に経口投与する。なお、年齢、症状により適宜増減する。
Contraindications / 禁忌
EN:
JA:
Regulatory Information / 規制情報
Approval No.: 22400AMX00127
Sales Started: September 2000 / 2000年9月
Classification Code: 87119
Storage: Store at room temperature / 室温保存
Shelf Life: 3 years / 3年
Packaging / 包装
Main Package (for sale): 28 tablets [14 tablets (PTP) x 2] / 28錠[14錠(PTP)×2]
Other Available Packages (by special order): 28 tablets [14 tablets (PTP) x 2], 140 tablets [14 tablets (PTP) x 10]
Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

![Ofloxacin Otic Solution 0.3% [CEO] (Ofloxacin Otic Solution CEO® / オフロキサシン耳科用液0.3%「CEO」)](https://jp-pharma.com/wp-content/uploads/2026/06/OFL-03-OTC_1200x1200-324x324.jpg)


Reviews
There are no reviews yet.